Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 8:03 PM
Ignite Modification Date:
2025-12-24 @ 8:03 PM
NCT ID:
NCT01288404
Brief Summary:
Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.
Detailed Description:
1. Impending recurrent pterygium
2. Anti-VEGF therapy
* Bevacizumab
* Subconjunctival injection
* Suppress neovascularization
Study:
NCT01288404
Study Brief:
Protocol Section:
NCT01288404